Sleep Review

24/01/2025

SICAT has introduced a new workflow for its Optisleep oral appliance, allowing dentists to order the device without the need for CBCT scans by using optical impressions. The company has also announced a partnership with Vatech, integrating its SICAT Suite of applications with Vatech’s 3D imaging software to support diagnostics and treatment planning for dental procedures, including sleep medicine and implantology.

SICAT introduces a CBCT-free workflow for its Optisleep oral appliance and partners with Vatech to integrate with its 3D imaging software.

23/01/2025

Help Shape the Future of Sleep Diagnostics. We’re exploring innovations in home sleep test technology, and your expertise is vital. If you work in sleep medicine, your insights will help guide the development of smarter tools for diagnostics and care.

https://buff.ly/4hiT4JC

22/01/2025

Waking up does not activate an increase in the release of the stress hormone cortisol. Cortisol does, however, increase in the hours prior to awakening as part of the body’s preparation for the next day, new research led by the University of Bristol has found.

It has been generally accepted that waking up results in a stimulus to release hormone cortisol—a phenomenon called the “cortisol awakening response.”

21/01/2025

VGM Group, Inc. has acquired SleepGlad, a Division of Baxter Technology Group, a company specializing in a cloud-based 3D mask-fitting platform for CPAP and noninvasive ventilation. SleepGlad’s AI-driven technology enables remote scanning and provides accurate, manufacturer-agnostic mask recommendations, aiming to improve patient outcomes and reduce the need for refittings.

The acquisition expands VGM Group’s sleep technology portfolio with a remote 3D mask-fitting platform designed to streamline care.

17/01/2025

Project Sleep Announces the 2025 Jack & Julie Narcolepsy Scholarship

Five of these scholarships will be awarded to students with idiopathic hypersomnia, thanks to a generous partnership with the Hypersomnia Foundation

Project Sleep's 2025 Jack & Julie Narcolepsy Scholarship will award 30 scholarships of $1000 each to college-bound students with narcolepsy & IH.

17/01/2025

A study found high concordance between the Onera STS and traditional PSG across essential sleep variables and key respiratory parameters, as well as substantial epoch-by-epoch agreement in sleep staging and comparable inter-scorer reliability between the two systems

A study demonstrates comparable performance between the wireless, patch-based Onera Sleep Test System and in-lab PSG.

16/01/2025

Subscribe today to ensure you get a free copy of the 2025 Buyer's Guide in the mail, the annual directory of sleep medicine companies, product categories, and brand names:

Sign up for emails, newsletters and print magazines from the leading Sleep Medicine Magazine and Journal

15/01/2025

The Headband That Promises Sleep, On Demand

Part sleep-tracking wearable, part electronic alternative to sleep supplements, this Elemind Technologies, Inc. EEG headband with acoustic modulation could be useful to sleep patients who prioritize convenience.

As a wellness product, Elemind is not FDA-cleared to diagnose or treat any sleep disorders. Still, it is an elegant option for sleep specialists to potentially proffer as an alternative for patients who’d otherwise favor pills. It can also be a sleep tracker adjunct to traditional insomnia management plans, with the added possibility of accelerating sleep onset.

Part sleep-tracking wearable, part electronic alternative to sleep supplements, the Elemind headband could be useful to sleep patients who prioritize convenience.

14/01/2025

Compumedics’ Somfit Sales Build Momentum in US and European Markets

Compumedics' US sales orders continue to grow, primarily by sleep, Somfit home sleep testing, and brain research business.

09/01/2025

The FDA has cleared Mineralys Therapeutics, Inc.'s Investigational New Drug application for a phase 2 clinical trial to evaluate the effect of lorundrostat in the treatment of subjects with moderate-to-severe OSA and hypertension.

Jon Congleton, CEO, says, “We believe suppression of aldosterone production by lorundrostat has the potential to reduce the nocturnal hypertension driving adverse cardiovascular outcomes. In addition, lorundrostat is anticipated to reduce the severity of upper airway obstruction and associated OSA symptoms such as daytime sleepiness and cognitive impairment.”

The trial will evaluate the drug’s potential to reduce upper airway obstruction and nocturnal hypertension in patients with OSA.

08/01/2025

Why and how the year 2025 could mark the start to an era of innovation for unattended sleep testing

New HST codes are being developed by the AASM, a clinical guideline patch is being drafted, and reimbursement fee changes will follow.

08/01/2025

Airflow sensors are used during sleep studies to measure and monitor the flow of breathing to help clinicians detect sleep-disordered breathing. They use various technologies, such as pressure transducers and polyvinylidene fluoride, to detect inhalation and exhalation.

Sleep Review's airflow sensor comparison guide is a comprehensive comparison of the major sensors available on the market.

30/12/2024

5 Viral Sleep Hacks of 2024: What’s Helping and What’s Hype

Michael Gradisar, PhD, and head of sleep science at Sleep Cycle, took a closer look at the evidence behind five of these viral phenomena and shared his insights on which ones worked and which ones fell flat.

❓ Mouth Taping
❓ Grounding Sheets
❓ Sleepy Girl Mocktail
❓ Digital Detox
❓ Sleep Divorce

Sleep Cycle’s Michael Gradisar, PhD, examines five of 2024’s viral sleep trends, revealing which ones works and which ones don't.

26/12/2024

This year, the four topics that garnered the most online engagement were all related to OSA therapy.
1. Philips Respironics Discontinues US CPAP Sales.
2. Positional Sleep Aids Generate Renewed Interest.
3. CPAP Masks with Magnets Contraindicated in Certain Patients.
4. Wins for Oral Appliance Therapy Credibility.

We reviewed reports from sleepreviewmag.com to curate this roundup of news that captivated sleep specialists in 2024.

23/12/2024

Breaking: Eli Lilly and Company announced the FDA approved Zepbound (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity.

Zepbound may help adults with moderate-to-severe obstructive sleep apnea and obesity improve their sleep disorder. It should be used with a reduced-calorie diet and increased physical activity.

The FDA has approved Zepbound as the first prescription medication for adults with obstructive sleep apnea (OSA) and obesity.